Who Needs Testosterone, and Who's Not Getting It I Signal Episode 4

Most men who start testosterone never needed it, and some who genuinely do never get treated. In the final episode of the Signal series, Dr. Jordan Feigenbaum and Dr. Austin Baraki work through who actually needs testosterone replacement, who got sold it, and what the evidence says about the risks that scared the field for a decade. We cover the blinded trial where men couldn't tell real testosterone from placebo, what the heart and prostate data actually show now that we have the trials, what testosterone does to fertility, and the framework we use to decide. We also close the story of Mark, the patient whose lab result started the series.
This is educational content, not medical advice. Talk to your physician about your personal situation.
Here we cover the real diagnosis of testosterone deficiency, primary versus secondary low testosterone, how the system both over- and under-prescribes, the SHBG trap that makes a normal level look low, the gray-zone crossover study, what replacement should actually target, why most men quit within a year, testosterone as a male contraceptive, the TRAVERSE cardiovascular results, the saturation model and prostate safety, the blood side effect worth monitoring, and when not to start at all.
Timestamps:
00:00 The study almost nobody mentions
01:31 Who this episode is for
03:35 What a real testosterone diagnosis requires
07:18 Primary vs secondary low testosterone
10:12 How testosterone gets over-prescribed
11:35 The SHBG trap: when a low number misleads
18:10 Would GLP-1 plus testosterone work better?
22:19 Why genuine deficiency gets under-treated
24:15 The cardiovascular scare and where it came from
34:11 The gray-zone study, in full
41:02 What TRT should actually target, and the "900" myth
47:38 Running TRT as a trial, and why 70% quit
52:36 Testosterone as a contraceptive: the fertility cost
57:19 Does TRT cause heart problems? The TRAVERSE trial
01:01:40 Testosterone and the prostate
01:09:13 The blood side effect worth watching
01:12:02 When not to start testosterone
01:14:26 Who actually benefits from TRT
01:18:28 The Signal framework, and what happened to Mark
01:21:14 Five things to take away
01:23:33 Our conflict of interest, and the book
Resources:
Buy the book, Signal: https://www.barbellmedicine.com/shop/learning/signal/
Part 1: Is the testosterone crisis real?
Part 2: Is you testosterone actually low?
Part 3: What's actually driving your testosterone down?
New Barbell Medicine Hybrid 5K and 10K Run + Lift Programs
Barbell Medicine coaching and templates: https://www.barbellmedicine.com
Testosterone Action Plan: https://www.barbellmedicine.com/testosterone-action-plan/
Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-769. doi:10.1111/j.1742-1241.2006.00992.x
Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001-2011. JAMA Intern Med. 2013;173(15):1465-1466. doi:10.1001/jamainternmed.2013.6895
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. doi:10.1016/j.juro.2018.03.115
Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) and European Society of Endocrinology (ESE) recommendations on the diagnosis and management of male hypogonadism. Andrology. 2020;8(5):970-987. doi:10.1111/andr.12770
Morgentaler A, Zitzmann M, Traish AM, et al. Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med. 2014;11(7):1636-1645. doi:10.1111/jsm.12546
Mok SF, Fennell C, Savkovic S, et al. Testosterone for androgen deficiency-like sympto...